# EDGAR Filing Document

**Accession Number:** 0001699737
**File Stem:** 0001415889-25-023605
**Filing Date:** 2025-9
**Character Count:** 16154
**Document Hash:** e0bb496838f2b0e8b1015aa697ad1493
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-023605.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0001415889-25-023605

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250903

**DATE AS OF CHANGE**: 20250903

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** vTv Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001641489
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473916571
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88973
- **FILM NUMBER:** 251291532

**BUSINESS ADDRESS:**
- **STREET 1:** 3980 PREMIER DR
- **STREET 2:** SUITE 310
- **CITY:** HIGH POINT
- **STATE:** NC
- **ZIP:** 27265
- **BUSINESS PHONE:** 336-841-0300

**MAIL ADDRESS:**
- **STREET 1:** 3980 PREMIER DR
- **STREET 2:** SUITE 310
- **CITY:** HIGH POINT
- **STATE:** NC
- **ZIP:** 27265

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VTV Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20150506
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Samsara BioCapital, L.P.
- **CENTRAL INDEX KEY:** 0001699737

**ORGANIZATION NAME:**
- **EIN:** 813958301
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** (650) 285-4270

**MAIL ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**VTV THERAPEUTICS INC.**

*(Name of Issuer)*

**Class A Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**918385204**

*(CUSIP Number)*

**Abrar Hussain**<br>Samsara BioCapital GP, LLC<br>628 Middlefield Road<br>Palo Alto CA 94301<br>(650) 285-4270

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/29/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **918385204** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samsara BioCapital, L.P.** | Name of reporting person<br>**Samsara BioCapital, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**339157.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**339157.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**339157.00** | Aggregate amount beneficially owned by each reporting person<br>**339157.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **918385204** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samsara BioCapital GP, LLC** | Name of reporting person<br>**Samsara BioCapital GP, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**339157.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**339157.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**339157.00** | Aggregate amount beneficially owned by each reporting person<br>**339157.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **918385204** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Srinivas Akkaraju** | Name of reporting person<br>**Srinivas Akkaraju** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4066.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**339157.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4066.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**339157.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**343223.00** | Aggregate amount beneficially owned by each reporting person<br>**343223.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.9%** | Percent of class represented by amount in Row (11)<br>**9.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
VTV THERAPEUTICS INC.

**(c) Address of Issuer's Principal Executive Offices:**
3980 Premier Drive, Suite 310, High Point, NC, 27265

This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on March 5, 2024 (the "Statement") by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

**Item 4. Purpose of Transaction**

Item 4 of the Statement is hereby amended and supplemented as follows:

The information included in Item 3 of this Amendment No. 1 is incorporated herein by reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of shares of Class A common stock and percentages of the shares of Class A common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of (i) 2,617,215 shares of Class A common stock outstanding as of August 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 12, 2025; (ii) 682,018 shares of Class A common stock issued in the private placement of equity securities by the Issuer that closed on September 3, 2025; (iii) 132,373 shares of Class A common stock issuable upon the exercise of Warrants; and (iv) with respect to Dr. Akkaraju, 4,066 shares of Class A common stock issuable upon the exercise of stock options within 60 days.

Due to field limitations of the EDGAR filing system, the percentage listed in Row 13 of the cover page for Dr. Akkaraju has been rounded down to 9.9%.

The Reporting Persons' beneficial ownership of the Issuer's Class A common stock consists of (i) 206,784 shares of Class A common stock directly held by Samsara LP; (ii) Pre-Funded Warrants exercisable for up to 1,548,101 shares of Class A common stock; (iii) Common Warrants exercisable for up to 655,523 shares of Class A common stock; and (iv) 4,066 stock options (right to buy) scheduled to vest within 60 days of this filing held by Dr. Akkaraju. Each of the Pre-Funded Warrants and the Common Warrants contains a provision (the "Beneficial Ownership Blockers") which precludes exercise of the Warrants to the extent that, following exercise, Samsara LP, together with its affiliates and other attribution parties, would own more than 9.99% of the Class A common stock outstanding. Samsara LP is currently prohibited from exercising the Warrants to the extent that such exercise would result in the Reporting Persons' beneficial ownership of more than 343,223 shares of Class A common stock.

Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP.

**(b)**
Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of Class A common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

**(c)**
Except as set forth elsewhere herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Statement is hereby amended and supplemented as follows:

The information included in Item 3 of this Amendment No. 1 is incorporated herein by reference.

Pre-Funded Warrants

The Pre-Funded Warrants are exercisable for $0.01 per share, at any time after their original issuance.

Common Warrants

The Common Warrants are exercisable for (x) $22.71, if exercised for a share of Class A common stock, or (y) $22.70, if exercised for a Pre-Funded Warrant, in either case, at any time after their original issuance, and will expire upon the earlier to occur of (i) the fifth anniversary of the issuance of the Common Warrants and (ii) 90 days following the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial.

Registration Rights Agreement

On August 29, 2025, the Issuer entered into a registration rights agreement (the "Registration Rights Agreement") with the August 2025 PIPE Investors, pursuant to which the Issuer agreed to register for resale the shares of Class A common stock and any shares of Class A common stock issuable upon exercise of the Pre-Funded Warrants and Common Warrants (collectively, the "Registrable Securities"), in accordance with the terms and conditions of the Registration Rights Agreement. Under the Registration Rights Agreement, the Issuer is required to file a shelf registration statement with the SEC covering the resale of the Registrable Securities on or prior to thirty (30) days following the closing of the August 2025 Private Placement and to usecommercially reasonable efforts to have such registration statement declared effective as soon as practicable, but no later than sixty (60) days after the closing (or ninety (90) days if the SEC reviews the registration statement), subject to certain permitted extensions.

The Issuer is required to use commercially reasonable efforts to keep such registration statement effective until the earlier of (i) the date all Registrable Securities have been sold, (ii) the date all Registrable Securities may be sold without restriction under Rule 144, or (iii) three (3) years after the initial effectiveness of the registration statement. The Issuer is responsible for all expenses in connection with the registration of the Registrable Securities, other than any selling commissions or underwriter discounts.

The Issuer has granted the August 2025 PIPE Investors customary indemnification rights in connection with the registration statement. The August 2025 PIPE Investors have also granted the Issuer customary indemnification rights in connection with the registration statement.

The foregoing descriptions of the Pre-Funded Warrants, the Common Warrants and the Registration Rights Agreement does not purport to be complete and are qualified in its entirety by reference to the form of Pre-Funded Warrant, Form of Common Warrant and Registration Rights Agreement, which are filed as Exhibits 99.3, 99.4 and 99.5, respectively, hereto and incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samsara BioCapital, L.P.

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member

**Date:** 09/03/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samsara BioCapital GP, LLC

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** By Srinivas Akkaraju, Managing Member

**Date:** 09/03/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Srinivas Akkaraju

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** Srinivas Akkaraju

**Date:** 09/03/2025